Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology

Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology PR Newswire PORTSMOUTH, New Hampshire, May 29, 2012 PORTSMOUTH, New Hampshire, May 29, 2012 /PRNewswire/ -- Novocure™, a commercial stage private oncology company, announced today that data from pre-clinical and clinical studies evaluating NovoTTF™ therapy will be presented and published online as part of the 48th Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, June 1-5, 2012. The data include the trial design of an ongoing Phase III (IDE) clinical trial of tumor-treating fields (TTFields) together with temozolomide compared to temozolomide (TMZ) alone in patients with newly diagnosed glioblastoma, and experimental data testing TTFields treatment in non-small cell lung cancer and pancreatic cancer. In addition to these updates, NovoTTF™ therapy will be highlighted at an ASCO Educational Session on Monday, June 4 at 1:15 pm in room S404 titled "Changing the Electrical Field around the Tumor Cell: How Does It Work and How Should We Use It?" The lecture will be presented by Dr. Philip H. Gutin, Chair of the Department of Neurosurgery and Co-Executive Director of the Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York. Changing the Electrical Field around the Tumor Cell: How Does It Work and How Should We Use It? Presenter: Dr. Philip H.